Form 4: Fennec Pharmaceuticals CEO Jeffrey Hackman Receives Stock Options and Restricted Share Units
SEC Form 4 Filing
CEO Jeffrey Hackman of Fennec Pharmaceuticals was granted stock options and restricted share units on March 28, 2025, according to a Form 4 filing.
Summary
- Jeffrey Hackman, CEO of Fennec Pharmaceuticals, received restricted share units and stock options on March 28, 2025.
- The restricted share units are for 75,000 common shares and were granted under the company's 2020 Equity Incentive Plan.
- These shares will vest in installments starting March 28, 2026, and will be fully vested by February 29, 2028.
- Hackman also received options to purchase 50,000 common shares at an exercise price of $6.50 per share.
- These options also vest in installments beginning March 28, 2026, and will be fully vested by February 29, 2028.
- Following these transactions, Hackman directly owns 75,000 restricted share units and 450,000 stock options.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The granting of stock options and restricted share units is a standard practice and aligns management's interests with shareholders. It suggests confidence in the company's future performance.
Positives
- The granting of stock options and restricted share units aligns the CEO's interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the CEO.
Industry Context
Granting stock options and restricted share units is a common practice in the pharmaceutical industry to incentivize and retain key executives.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the pharmaceutical industry.
- Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options and restricted stock units to incentivize their executives.
- The vesting schedules are fairly standard, with vesting typically occurring over a 3-year period.
Stakeholder Impact
- Shareholders may view the granting of stock options and restricted share units positively as it aligns management's interests with the company's long-term success.
- Employees may be motivated by the fact that the CEO is incentivized to improve the company's performance.
Key Dates
| Date | Description |
|---|---|
| 03/28/2025 | Date of the transaction: Jeffrey Hackman was awarded restricted share units and stock options. |
| 03/28/2026 | Vesting Commencement Date: One-third of the shares subject to the restricted share units and options will be released from restriction. |
| 02/29/2028 | Date when 100% of the total number of shares subject to the restricted share units and options will be released from restriction. |
| 03/28/2035 | Expiration date of the restricted share units and stock options. |
| 04/03/2025 | Date of the Form 4 filing. |
Keywords
Fennec Pharmaceuticals, Jeffrey Hackman, stock options, restricted share units, equity incentive plan, Form 4, executive compensation, vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.